MTOR and head and neck squamous cell carcinoma: mTOR inhibitors were the first to be tested in HNSCC as a monotherapy [everolimus (6), temsirolimus (7)] and in a combination with erlotinib (8, 9), but did not show a clinical benefit in terms of median progression free survival (PFS) or overall survival (OS).